Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 2

A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease

NCT07128628 · View on ClinicalTrials.gov ↗

Study Summary

A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease

Conditions Studied

Interventions

  • DRUG Vehicle
  • DRUG Lifitegrast/Perfluorohexyloctane Fixed Dose Combination
  • DRUG Lifitegrast
  • DRUG Perfluorohexyloctane

Study Locations (20)

California

  • Global Research Management, Inc. — Glendale
  • SoCal Eye - Lakewood Clinic — Long Beach
  • LoBue Laser and Eye Medical Center — Murrieta
  • Eye Research Foundation, Inc. — Newport Beach
  • Wolstan and Goldberg Eye Associates — Torrance

Missouri

  • Insight Eyecare Specialties, Inc. — Kansas City
  • Moyes Eye Center, P.C. — Kansas City
  • Ophthalmology Consultants, Ltd. — St Louis
  • Comprehensive Eye Care Ltd. — Washington

Florida

  • Segal Drug Trials/Office of Bruce A Segal, MD — Delray Beach
  • Bowden Eye and Associates — Jacksonville
  • Shettle Eye Research, Inc — Largo

Minnesota

  • Vance Thompson Vision - Alexandria — Alexandria
  • Complete Eye Care of Medina — Medina

New York

  • Opthalmic consultants of Long Island — Garden City
  • Rochester Ophthalmological Group,PC — Rochester

Arizona

  • Eye Doctors of Arizona, PLLC — Phoenix

Georgia

  • Clayton Eye Clinical Research, LLC — Morrow

Indiana

  • Midwest Cornea Associates LLC — Carmel

Trial Details

FieldValue
Enrollment Target 423 participants
Start Date 2025-10-24
Est. Completion 2026-11
Phase Phase 2

Sponsor

Bausch & Lomb Incorporated

78 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07128628

The ClinicalTrials.gov registry entry for NCT07128628 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 423 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 78 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 4 interventions — of which Vehicle is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07128628 reports 20 study locations spanning 9 distinct geographic areas — top geographies include California, Missouri, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07128628 about?

NCT07128628 is a clinical study titled "A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease". A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease

What is the current status of trial NCT07128628?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 423 participants. The study started on 2025-10-24. Estimated completion is 2026-11.

What conditions does trial NCT07128628 study?

This clinical trial studies the following conditions: Dry Eye Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07128628?

The interventions under investigation include: Vehicle (DRUG), Lifitegrast/Perfluorohexyloctane Fixed Dose Combination (DRUG), Lifitegrast (DRUG), Perfluorohexyloctane (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07128628?

This trial is sponsored by Bausch & Lomb Incorporated, which has 78 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07128628 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial